No. of Recommendations: 1
i think this stock has astronimical upside. anyone else
own it or have any thoughts on it. i think its a no brainer

From the Fool's report, it sounds like it has astronomical upside and astronomical downside as well.

Celsion (NASDAQ: CLSN) traded flat for the first six months of the year, but has picked up considerable momentum this fall now that results from the phase III study of its liver cancer therapy ThermoDox have been confirmed for release in January. Celsion's claim to fame is ThermoDox, a drug based on the company's Lysolipid Thermally Sensitive Liposomes (LTSL) platform being tested in a variety of cancers. The results won't be released until early next year, so consider this the beginning of the speculative fury, with things only intensifying into January.

Make no mistake -- there is significant upside for investors if the liver cancer trial results are good, but the downside is equally massive if ThermoDox were to fail. And those who invest in Celsion while ignoring that risk do so at their own peril. If the phase III study should fail, Celsion will be on the list of worst performing biotech stocks for 2013.

The company has lost money over the last three years. ROE is a high negative number. I'd wait and see how things pan out with them .

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.